Cargando…

Cutaneous manifestations of COVID-19 patients in a Hospital in São Paulo, Brazil, and global literature review()

BACKGROUND: Since the beginning of the COVID-19 pandemic, a myriad of cutaneous manifestations have been described in association with this viral infection. However, in Latin America, this kind of data is still scarce. OBJECTIVE: In this sense, the goal of this study was to describe the dermatologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Cestari, Silmara da Costa Pereira, Cestari, Marcela da Costa Pereira, Marques, Gabriela Franco, Lirio, Ivana, Tovo, Reinaldo, Cruz Silva Labriola, Ilana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9998298/
https://www.ncbi.nlm.nih.gov/pubmed/36964106
http://dx.doi.org/10.1016/j.abd.2022.09.007
Descripción
Sumario:BACKGROUND: Since the beginning of the COVID-19 pandemic, a myriad of cutaneous manifestations have been described in association with this viral infection. However, in Latin America, this kind of data is still scarce. OBJECTIVE: In this sense, the goal of this study was to describe the dermatological findings observed during SARS-CoV-2 infection, in a Brazilian Hospital. METHODS: This is a cross-sectional, retrospective and descriptive study of 50 cases of new-onset dermatologic symptoms in patients with COVID-19, treated at Hospital Sírio-Libanês, from February to June 2020. RESULTS: The patients (n = 50) were classified into 6 groups, according to the elementary lesions and the statistical analysis was performed. The most common cutaneous lesions were maculopapular eruptions (44%), necrosis, purpura, and livedo (32%), urticarial lesions (12%), pseudochilblains (4%) and papular-vesicular eruption (4%). In 46% of the patients the cutaneous lesions occurred in association with other symptoms, such as pruritus (38%), pain and burning sensation (8%). Lower limbs were affected in 44% of the cases, followed by the trunk (38%), upper limbs (24%) and face (14%). Cutaneous lesions were mostly found after other COVID-19 systemic symptoms, with a mean period between the viral syndrome and cutaneous signs of 5 days (SD = 6.1 days). STUDY LIMITATIONS: It is a small sample, in a single-center study, with patients exclusively from a private Hospital. CONCLUSIONS: Patients in Brazil have the same proportion of lesions as revealed in other studies in Europa. The compiled data is essential for a better understanding of cutaneous manifestations deemed secondary to COVID.